Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2007 1
2011 1
2012 1
2013 2
2014 1
2015 6
2016 4
2017 8
2018 4
2019 6
2020 8
2021 8
2022 9
2023 20
2024 13

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

78 results

Results by year

Filters applied: . Clear all
Page 1
Differential diagnosis of suspected multiple sclerosis: an updated consensus approach.
Solomon AJ, Arrambide G, Brownlee WJ, Flanagan EP, Amato MP, Amezcua L, Banwell BL, Barkhof F, Corboy JR, Correale J, Fujihara K, Graves J, Harnegie MP, Hemmer B, Lechner-Scott J, Marrie RA, Newsome SD, Rocca MA, Royal W 3rd, Waubant EL, Yamout B, Cohen JA. Solomon AJ, et al. Among authors: amezcua l. Lancet Neurol. 2023 Aug;22(8):750-768. doi: 10.1016/S1474-4422(23)00148-5. Lancet Neurol. 2023. PMID: 37479377 Review.
Progressive Multiple Sclerosis.
Amezcua L. Amezcua L. Continuum (Minneap Minn). 2022 Aug 1;28(4):1083-1103. doi: 10.1212/CON.0000000000001157. Continuum (Minneap Minn). 2022. PMID: 35938658 Review.
Dimethyl Fumarate Delays Multiple Sclerosis in Radiologically Isolated Syndrome.
Okuda DT, Kantarci O, Lebrun-Frénay C, Sormani MP, Azevedo CJ, Bovis F, Hua LH, Amezcua L, Mowry EM, Hotermans C, Mendoza J, Walsh JS, von Hehn C, Vargas WS, Donlon S, Naismith RT, Okai A, Pardo G, Repovic P, Stüve O, Siva A, Pelletier D. Okuda DT, et al. Among authors: amezcua l. Ann Neurol. 2023 Mar;93(3):604-614. doi: 10.1002/ana.26555. Epub 2022 Dec 10. Ann Neurol. 2023. PMID: 36401339 Clinical Trial.
Blood-brain barrier breakdown in the aging human hippocampus.
Montagne A, Barnes SR, Sweeney MD, Halliday MR, Sagare AP, Zhao Z, Toga AW, Jacobs RE, Liu CY, Amezcua L, Harrington MG, Chui HC, Law M, Zlokovic BV. Montagne A, et al. Among authors: amezcua l. Neuron. 2015 Jan 21;85(2):296-302. doi: 10.1016/j.neuron.2014.12.032. Neuron. 2015. PMID: 25611508 Free PMC article.
Risk of new disease activity in patients with multiple sclerosis who continue or discontinue disease-modifying therapies (DISCOMS): a multicentre, randomised, single-blind, phase 4, non-inferiority trial.
Corboy JR, Fox RJ, Kister I, Cutter GR, Morgan CJ, Seale R, Engebretson E, Gustafson T, Miller AE; DISCOMS investigators. Corboy JR, et al. Lancet Neurol. 2023 Jul;22(7):568-577. doi: 10.1016/S1474-4422(23)00154-0. Lancet Neurol. 2023. PMID: 37353277 Clinical Trial.
Differential diagnosis of suspected multiple sclerosis: considerations in people from minority ethnic and racial backgrounds in North America, northern Europe, and Australasia.
Amezcua L, Rotstein D, Shirani A, Ciccarelli O, Ontaneda D, Magyari M, Rivera V, Kimbrough D, Dobson R, Taylor B, Williams M, Marrie RA, Banwell B, Hemmer B, Newsome SD, Cohen JA, Solomon AJ, Royal W 3rd. Amezcua L, et al. Lancet Neurol. 2024 Oct;23(10):1050-1062. doi: 10.1016/S1474-4422(24)00288-6. Lancet Neurol. 2024. PMID: 39304244 Review.
78 results